12 NOV 2014: Valley View, OH – Great Lakes NeuroTechnologies announced today they have successfully transitioned their Kinesia technology for objective monitoring of Parkinson’s disease to an app platform. Kinesia ONE™ [https://glneurotech.com/kinesia/] uses a patient worn sensor and iPad mini app to objectively measure Parkinson’s symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements). Cloud storage and a web application make symptom data and reports available to clinicians and researchers. The company is strategically transitioning their Parkinson’s tech to app based systems, with Kinesia ONE marking the first step. Kinesia technology is FDA cleared to market, CE marked, and is TGA and Health Canada approved.
GLNT commercialized Kinesia technology to provide objective and automated assessment of movement disorder symptoms for clinical trials and telemedicine applications. “While Kinesia technology has been successfully integrated into a growing number of clinical trials by pharmaceutical and medical device manufacturers over the past year, accessibility has remained a barrier to wide scale adoption” says Thomas Mera, Product Development Manager. “Expanding our Kinesia product portfolio to include app based platforms significantly improves accessibility for individuals with Parkinson’s disease.”
Kinesia ONE uses a patient worn motion sensor to assess Parkinson’s symptoms, while specific tasks are performed using feedback from the app. Task-based motor assessments provide high sensitivity data for clinical trials. A high level of both accuracy and sensitivity in symptom measurement play an important role when integrating objective measures into Parkinson’s clinical trials, or in closed-loop control strategies for medication release or deep brain stimulation. Since 2007 Great Lakes NeuroTech has completed more than twenty clinical studies, domestically and internationally, to validate objective scoring algorithms for Parkinson’s motor symptoms using patient worn sensors. More than 800 individuals with Parkinson’s have participated, contributing greatly to both this technology and a cloud database of wide ranging symptom data for developing intelligent assessment and control algorithms.
Great Lakes NeuroTech indicated they have also developed continuous monitoring algorithms for measuring Parkinson’s disease. Kinesia 360™, planned for a January product release, will also be app based and focus on continuous monitoring. Patients will no longer need to complete specific tasks, but instead wear sensors while they go about their daily lives, and symptom severity is continually captured. This will further reduce patient burden for objective assessment of Parkinson’s disease. The company has secured significant intellectual property protection for objective monitoring of Parkinson’s disease including five U.S. patents in the last sixteen months.
The company thanked the National Institute of Health for supporting this development through the SBIR program, specifically the National Institute of Neurological Disorders and Stroke (5R44NS065554).
About Great Lakes NeuroTechnologies
Great Lakes NeuroTechnologies [ https://www.glneurotech.com ] is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.
Lori Grim, 216-361-5410 – lgrim@GLNeuroTech.com